RxDoctor Payments Data

John Mulrow, MD

Cardiovascular Disease · San Antonio, TXNPI 1043297922

Payments from drug & device makers

$2,741in general payments, 2019–2025

Across 86 payments — averaging $31.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Novartis$770
  • Pfizer$192
  • Merck$150
  • Medtronic$103
  • Amarin Pharma, Inc.$59
  • plus $238 from 8 others

What the payments were for

  • Travel & lodging$82330%
  • Food & beverage$1,89669%
  • Education$221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,741 in reported general payments places this provider in the 40th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$194,818
Medicare patients
629
Services billed
2,608

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban199$247,833
EntrestoSacubitril/Valsartan89$100,373
Repatha SureclickEvolocumab69$95,807
XareltoRivaroxaban22$28,839
FarxigaDapagliflozin Propanediol31$28,434
JardianceEmpagliflozin13$21,723
VascepaIcosapent Ethyl18$14,503
Ezetimibe349$8,308
Atorvastatin Calcium690$5,902
Candesartan Cilexetil30$2,618
Metoprolol Succinate175$2,554
Nebivolol Hcl36$2,441
Rosuvastatin Calcium215$2,387
ClopidogrelClopidogrel Bisulfate166$2,023
Amlodipine Besylate336$1,800

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$192$247,833199 claims
NovartisEntresto$770$100,37389 claims
Johnson & JohnsonXarelto$42$28,83922 claims
AstraZenecaFarxiga$15$28,43431 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →